First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

ClinicalTrials.gov ID: NCT01097746

Public ClinicalTrials.gov record NCT01097746. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Bevacizumab With Carboplatin and Weekly Paclitaxel as First-Line Treatment in Epithelial Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial studies how well first-line treatment of bevacizumab, carboplatin, and paclitaxel work in treating participants with stage III- IV ovarian, primary peritoneal and fallopian tube cancer. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving bevacizumab, carboplatin, and paclitaxel as first-line treatment may work better at treating ovarian, primary peritoneal, and fallopian tube cancer.

Study identification

NCT ID: NCT01097746
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: M.D. Anderson Cancer Center; Other
Enrollment: 33 participants

Conditions and interventions

Conditions

Interventions

Bevacizumab Biological
Carboplatin Drug
Paclitaxel Drug

Biological · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 13, 2010
Primary completion: Dec 6, 2021
Completion: Sep 12, 2022
Last update posted: Oct 27, 2022

2010 – 2022

United States locations

U.S. sites: 5
U.S. states: 1
U.S. cities: 4

Facility	City	State	ZIP	Site status
M D Anderson Cancer Center	Houston	Texas	77030	—
MD Anderson Regional Care Center-Katy	Houston	Texas	77094	—
MD Anderson Regional Care Center-Bay Area	Nassau Bay	Texas	77058	—
MD Anderson Regional Care Center-Sugar Land	Sugar Land	Texas	77478	—
MD Anderson Regional Care Center-The Woodlands	The Woodlands	Texas	77384	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01097746, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 27, 2022 · Synced Sep 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01097746 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →